Merck Company Stock Price To Earnings To Growth

MRK Stock

USD 99.86 2.42 2.48%

Merck Company fundamentals help investors to digest information that contributes to Merck's financial success or failures. It also enables traders to predict the movement of Merck Stock. The fundamental analysis module provides a way to measure Merck's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Merck stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Merck Company Company Price To Earnings To Growth Analysis

Merck's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.

PEG Ratio

PE Ratio

EPS Growth

More About Price To Earnings To Growth | All Equity Analysis

Current Merck Price To Earnings To Growth

0.07 X

Most of Merck's fundamental indicators, such as Price To Earnings To Growth, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Merck Company is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Merck Price To Earnings To Growth Driver Correlations

Understanding the fundamental principles of building solid financial models for Merck is extremely important. It helps to project a fair market value of Merck Stock properly, considering its historical fundamentals such as Price To Earnings To Growth. Since Merck's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Merck's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Merck's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Short Term Investments	Capital Stock	Common Stock	Long Term Debt	Good Will	Treasury Stock	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Total Permanent Equity	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Accumulated Depreciation	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital
Total Assets		0.87	0.28	0.88	0.57	0.7	0.98	0.3	0.8	0.5	0.16	0.95	0.95	0.73	0.65	-0.27	0.44	-0.21	-0.22	0.19	0.35	0.22	0.36	0.31	-0.7	0.02	0.19	0.2	0.15
Total Stockholder Equity	0.87		-0.07	0.59	0.4	0.4	0.9	0.07	0.93	0.06	0.37	0.72	0.72	0.36	0.22	0.18	0.21	-0.26	0.23	-0.07	-0.02	0.1	0.61	0.48	-0.48	-0.37	-0.07	0.16	0.35
Net Debt	0.28	-0.07		0.57	0.74	0.83	0.18	0.11	-0.09	0.74	-0.2	0.42	0.42	0.74	0.71	-0.89	0.5	0.52	-0.58	0.54	0.82	0.58	-0.42	-0.26	-0.43	0.32	0.56	0.48	-0.1
Retained Earnings	0.88	0.59	0.57		0.65	0.83	0.84	0.26	0.5	0.81	0.01	0.9	0.9	0.91	0.89	-0.65	0.58	0.03	-0.48	0.37	0.65	0.37	0.04	0.04	-0.74	0.24	0.48	0.37	0.18
Net Receivables	0.57	0.4	0.74	0.65		0.88	0.53	0.06	0.44	0.57	-0.28	0.59	0.59	0.65	0.53	-0.61	0.7	0.54	-0.3	0.5	0.59	0.72	0.07	-0.26	-0.53	-0.05	0.6	0.62	0.2
Total Liab	0.7	0.4	0.83	0.83	0.88		0.64	0.35	0.4	0.76	-0.17	0.78	0.78	0.81	0.78	-0.77	0.56	0.25	-0.59	0.52	0.65	0.45	-0.05	-0.09	-0.75	0.28	0.46	0.38	-0.03
Total Current Assets	0.98	0.9	0.18	0.84	0.53	0.64		0.3	0.82	0.42	0.21	0.91	0.91	0.64	0.55	-0.18	0.4	-0.25	-0.12	0.15	0.24	0.18	0.38	0.33	-0.71	-0.06	0.18	0.16	0.19
Short Term Debt	0.3	0.07	0.11	0.26	0.06	0.35	0.3		0.11	0.28	-0.27	0.4	0.4	0.14	0.26	-0.23	0.03	-0.43	-0.48	0.19	-0.12	-0.34	-0.05	0.08	-0.63	0.74	-0.13	-0.42	-0.64
Intangible Assets	0.8	0.93	-0.09	0.5	0.44	0.4	0.82	0.11		0.08	0.15	0.65	0.65	0.29	0.16	0.19	0.28	-0.21	0.14	-0.05	-0.05	0.11	0.75	0.25	-0.47	-0.31	-0.09	0.14	0.22
Accounts Payable	0.5	0.06	0.74	0.81	0.57	0.76	0.42	0.28	0.08		-0.36	0.59	0.59	0.86	0.91	-0.91	0.64	0.27	-0.74	0.45	0.81	0.4	-0.33	-0.38	-0.64	0.54	0.59	0.41	-0.05
Short Term Investments	0.16	0.37	-0.2	0.01	-0.28	-0.17	0.21	-0.27	0.15	-0.36		0.14	0.14	-0.11	-0.14	0.39	-0.55	-0.48	0.36	-0.28	-0.27	-0.35	0.22	0.77	0.11	-0.4	-0.48	-0.3	0.08
Capital Stock	0.95	0.72	0.42	0.9	0.59	0.78	0.91	0.4	0.65	0.59	0.14		1.0	0.77	0.76	-0.42	0.38	-0.27	-0.43	0.3	0.38	0.19	0.24	0.29	-0.7	0.21	0.23	0.06	-0.03
Common Stock	0.95	0.72	0.42	0.9	0.59	0.78	0.91	0.4	0.65	0.59	0.14	1.0		0.77	0.76	-0.42	0.38	-0.27	-0.43	0.3	0.38	0.19	0.24	0.29	-0.7	0.21	0.23	0.06	-0.03
Long Term Debt	0.73	0.36	0.74	0.91	0.65	0.81	0.64	0.14	0.29	0.86	-0.11	0.77	0.77		0.93	-0.76	0.67	0.23	-0.52	0.41	0.88	0.56	-0.2	-0.09	-0.58	0.24	0.6	0.49	0.11
Good Will	0.65	0.22	0.71	0.89	0.53	0.78	0.55	0.26	0.16	0.91	-0.14	0.76	0.76	0.93		-0.83	0.51	0.07	-0.75	0.5	0.79	0.33	-0.2	-0.1	-0.56	0.49	0.51	0.28	-0.02
Treasury Stock	-0.27	0.18	-0.89	-0.65	-0.61	-0.77	-0.18	-0.23	0.19	-0.91	0.39	-0.42	-0.42	-0.76	-0.83		-0.55	-0.44	0.77	-0.56	-0.83	-0.46	0.51	0.43	0.51	-0.54	-0.67	-0.4	0.07
Property Plant Equipment	0.44	0.21	0.5	0.58	0.7	0.56	0.4	0.03	0.28	0.64	-0.55	0.38	0.38	0.67	0.51	-0.55		0.61	-0.23	0.39	0.71	0.84	-0.05	-0.6	-0.41	0.04	0.85	0.75	0.24
Current Deferred Revenue	-0.21	-0.26	0.52	0.03	0.54	0.25	-0.25	-0.43	-0.21	0.27	-0.48	-0.27	-0.27	0.23	0.07	-0.44	0.61		0.07	0.28	0.58	0.81	-0.33	-0.65	0.07	-0.25	0.66	0.85	0.43
Net Tangible Assets	-0.22	0.23	-0.58	-0.48	-0.3	-0.59	-0.12	-0.48	0.14	-0.74	0.36	-0.43	-0.43	-0.52	-0.75	0.77	-0.23	0.07		-0.51	-0.46	0.02	0.23	0.33	0.4	-0.82	-0.31	0.14	0.45
Total Permanent Equity	0.19	-0.07	0.54	0.37	0.5	0.52	0.15	0.19	-0.05	0.45	-0.28	0.3	0.3	0.41	0.5	-0.56	0.39	0.28	-0.51		0.43	0.31	0.0	-0.35	-0.3	0.25	0.41	0.25	-0.04
Long Term Debt Total	0.35	-0.02	0.82	0.65	0.59	0.65	0.24	-0.12	-0.05	0.81	-0.27	0.38	0.38	0.88	0.79	-0.83	0.71	0.58	-0.46	0.43		0.72	-0.42	-0.38	-0.31	0.18	0.74	0.69	0.18
Capital Surpluse	0.22	0.1	0.58	0.37	0.72	0.45	0.18	-0.34	0.11	0.4	-0.35	0.19	0.19	0.56	0.33	-0.46	0.84	0.81	0.02	0.31	0.72		-0.14	-0.47	-0.08	-0.29	0.82	0.84	0.39
Deferred Long Term Liab	0.36	0.61	-0.42	0.04	0.07	-0.05	0.38	-0.05	0.75	-0.33	0.22	0.24	0.24	-0.2	-0.2	0.51	-0.05	-0.33	0.23	0.0	-0.42	-0.14		0.15	0.01	-0.33	-0.33	-0.14	0.08
Long Term Investments	0.31	0.48	-0.26	0.04	-0.26	-0.09	0.33	0.08	0.25	-0.38	0.77	0.29	0.29	-0.09	-0.1	0.43	-0.6	-0.65	0.33	-0.35	-0.38	-0.47	0.15		-0.03	-0.22	-0.6	-0.43	0.01
Accumulated Depreciation	-0.7	-0.48	-0.43	-0.74	-0.53	-0.75	-0.71	-0.63	-0.47	-0.64	0.11	-0.7	-0.7	-0.58	-0.56	0.51	-0.41	0.07	0.4	-0.3	-0.31	-0.08	0.01	-0.03		-0.35	-0.17	-0.15	0.12
Short Long Term Debt	0.02	-0.37	0.32	0.24	-0.05	0.28	-0.06	0.74	-0.31	0.54	-0.4	0.21	0.21	0.24	0.49	-0.54	0.04	-0.25	-0.82	0.25	0.18	-0.29	-0.33	-0.22	-0.35		0.07	-0.34	-0.65
Cash And Equivalents	0.19	-0.07	0.56	0.48	0.6	0.46	0.18	-0.13	-0.09	0.59	-0.48	0.23	0.23	0.6	0.51	-0.67	0.85	0.66	-0.31	0.41	0.74	0.82	-0.33	-0.6	-0.17	0.07		0.67	0.34
Net Invested Capital	0.2	0.16	0.48	0.37	0.62	0.38	0.16	-0.42	0.14	0.41	-0.3	0.06	0.06	0.49	0.28	-0.4	0.75	0.85	0.14	0.25	0.69	0.84	-0.14	-0.43	-0.15	-0.34	0.67		0.64
Net Working Capital	0.15	0.35	-0.1	0.18	0.2	-0.03	0.19	-0.64	0.22	-0.05	0.08	-0.03	-0.03	0.11	-0.02	0.07	0.24	0.43	0.45	-0.04	0.18	0.39	0.08	0.01	0.12	-0.65	0.34	0.64

Click cells to compare fundamentals

Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.

Competition

Predict Merck

Merck Price Earnings To Growth Ratio

Price Earnings To Growth Ratio

(7.58)

At this time, Merck's Price Earnings To Growth Ratio is quite stable compared to the past year.

Based on the latest financial disclosure, Merck Company has a Price To Earnings To Growth of 0.0678 times. This is 90.45% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The price to earnings to growth for all United States stocks is 98.61% higher than that of the company.

Merck Price To Earnings To Growth Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Merck's direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Merck could also be used in its relative valuation, which is a method of valuing Merck by comparing valuation metrics of similar companies.

Merck is currently under evaluation in price to earnings to growth category among its peers.

Merck ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Merck's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Merck's managers, analysts, and investors.

Environmental

Governance

Social

Merck Fundamentals

	Return On Equity	0.28
	Return On Asset	0.11
	Profit Margin	0.19 %
	Operating Margin	0.26 %
	Current Valuation	270.03 B
	Shares Outstanding	2.53 B
	Shares Owned By Insiders	0.06 %
	Shares Owned By Institutions	79.37 %
	Number Of Shares Shorted	26.23 M
	Price To Earning	18.05 X
	Price To Book	5.54 X
	Price To Sales	3.90 X
	Revenue	60.12 B
	Gross Profit	42.08 B
	EBITDA	6.91 B
	Net Income	365 M
	Cash And Equivalents	12.69 B
	Cash Per Share	4.44 X
	Total Debt	36.27 B
	Debt To Equity	0.68 %
	Current Ratio	1.46 X
	Book Value Per Share	17.58 X
	Cash Flow From Operations	13.01 B
	Short Ratio	2.75 X
	Earnings Per Share	4.82 X
	Price To Earnings To Growth	0.07 X
	Target Price	131.08
	Number Of Employees	70 K
	Beta	0.41
	Market Capitalization	246.49 B
	Total Asset	106.67 B
	Retained Earnings	53.9 B
	Working Capital	6.47 B
	Current Asset	29.76 B
	Current Liabilities	19.2 B
	Annual Yield	0.03 %
	Five Year Return	2.99 %
	Net Asset	106.67 B
	Last Dividend Paid	3.04

About Merck Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Merck Company's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Merck using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Merck Company based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Merck Company is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Merck Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Merck Company Stock. Highlighted below are key reports to facilitate an investment decision about Merck Company Stock:

How To Invest In Merck

Details

Is Merck Stock a good investment?

Details

What is Merck's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Merck Piotroski F Score and Merck Altman Z Score analysis.

You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. If investors know Merck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merck listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.33)

Dividend Share

3.04

Earnings Share

4.82

Revenue Per Share

24.931

Quarterly Revenue Growth

0.044

The market value of Merck Company is measured differently than its book value, which is the value of Merck that is recorded on the company's balance sheet. Investors also form their own opinion of Merck's value that differs from its market value or its book value, called intrinsic value, which is Merck's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merck's market value can be influenced by many factors that don't directly affect Merck's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Merck Company Stock Price To Earnings To Growth

Merck Company Company Price To Earnings To Growth Analysis

PEG Ratio

PE Ratio

EPS Growth

Current Merck Price To Earnings To Growth

Merck Price To Earnings To Growth Driver Correlations

Merck Price Earnings To Growth Ratio

Price Earnings To Growth Ratio

(7.58)

Merck Price To Earnings To Growth Peer Comparison

Merck ESG Sustainability

Merck Fundamentals

About Merck Fundamental Analysis

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY